BPC

The Wolverine peptide stack offers a range of regenerative, protective, and analgesic benefits by combining the BPC-157 and TB-500 peptides.

Researchers may also find relevant context in our guide to The Complete Guide to Peptide Stacking: How to Combine Research Peptides for Maximum Results.

Athletes and fitness enthusiasts could benefit the most from using the Wolverine peptide stack regularly. However, anyone needing faster healing, injury repair, and pain reduction could benefit from it.

Anyone taking part in intense training and injury-prone activities could benefit from the protective and regenerative qualities the Wolverine peptide stack offers.

BPC-157 and TB-500 are the most discussed regenerative peptides in longevity circles. Here is what the animal research shows, how practitioners use them, and what you need to know about safety and sourcing.

BPC-157 / TB-500 (Moderate evidence) — two of the most discussed compounds in the intersection of regenerative medicine and longevity. Their appeal is straightforward: faster recovery from injuries means more consistent exercise, and consistent exercise is the single most impactful longevity intervention available. An athlete sidelined for months with a torn tendon or a weekend warrior nursing chronic tendinopathy cannot train, and the compounding effect of missed training weeks is significant over years and decades.

The challenge with discussing these peptides honestly is that the enthusiasm in the longevity community has dramatically outpaced the evidence base. BPC-157 has extensive and genuinely impressive animal research. TB-500 (synthetic thymosin beta-4) has solid wound healing data. But neither has a single published, peer-reviewed, randomized controlled trial in humans for injury recovery. This does not mean they do not work. It means we do not have the standard of evidence that normally precedes widespread adoption of a therapeutic compound.

BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids derived from a protective protein found in human gastric juice. It was first characterized by Dr. Predrag Sikiric and colleagues at the University of Zagreb, who have published the majority of the research on this compound. Their work, spanning over two decades, has demonstrated healing effects across a remarkable range of tissue types in animal models.

A comprehensive review by Sikiric et al. published in Current Neuropharmacology documented BPC-157’s effects across multiple injury types:

The mechanism appears to involve modulation of the nitric oxide system, promotion of angiogenesis (new blood vessel formation), growth hormone receptor upregulation, and activation of the FAK-paxillin signaling pathway that governs cell migration and tissue repair. For the broader context of how peptides fit into longevity strategies, see our BPC-157 / TB-500 intervention page (Moderate evidence).

The critical caveat: All of this data comes from animal models. The dose translation from rats to humans is not straightforward, the injury models are artificially created, and the endpoints measured in animals do not always predict human outcomes. Dr. Sikiric’s group has conducted the vast majority of BPC-157 research, which means the findings have not been widely replicated by independent laboratories.

All 🧠 Anabolic Education 🚀 Elite Performance Strategies 🔬 Hormone Health & Optimization 🏛️ Inside Olympian 🥩 Nutrition & Recovery 🧬 Peptide Therapy & Regenerative Compounds 💪 Stacks & Protocols 👩‍⚕️ Women’s Performance & Hormone Health

BPC-157 and TB-500 are the most discussed regenerative peptides in longevity circles. Here is what the animal research shows, how practitioners use them, and what you need to know about safety and sourcing.

BPC-157 / TB-500 (Moderate evidence) — two of the most discussed compounds in the intersection of regenerative medicine and longevity. Their appeal is straightforward: faster recovery from injuries means more consistent exercise, and consistent exercise is the single most impactful longevity intervention available. An athlete sidelined for months with a torn tendon or a weekend warrior nursing chronic tendinopathy cannot train, and the compounding effect of missed training weeks is significant over years and decades.

The challenge with discussing these peptides honestly is that the enthusiasm in the longevity community has dramatically outpaced the evidence base. BPC-157 has extensive and genuinely impressive animal research. TB-500 (synthetic thymosin beta-4) has solid wound healing data. But neither has a single published, peer-reviewed, randomized controlled trial in humans for injury recovery. This does not mean they do not work. It means we do not have the standard of evidence that normally precedes widespread adoption of a therapeutic compound.

BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids derived from a protective protein found in human gastric juice. It was first characterized by Dr. Predrag Sikiric and colleagues at the University of Zagreb, who have published the majority of the research on this compound. Their work, spanning over two decades, has demonstrated healing effects across a remarkable range of tissue types in animal models.

A comprehensive review by Sikiric et al. published in Current Neuropharmacology documented BPC-157’s effects across multiple injury types:

The mechanism appears to involve modulation of the nitric oxide system, promotion of angiogenesis (new blood vessel formation), growth hormone receptor upregulation, and activation of the FAK-paxillin signaling pathway that governs cell migration and tissue repair. For the broader context of how peptides fit into longevity strategies, see our BPC-157 / TB-500 intervention page (Moderate evidence).

The critical caveat: All of this data comes from animal models. The dose translation from rats to humans is not straightforward, the injury models are artificially created, and the endpoints measured in animals do not always predict human outcomes. Dr. Sikiric’s group has conducted the vast majority of BPC-157 research, which means the findings have not been widely replicated by independent laboratories.

The BPC-157, TB-500, KPV & GHK-Cu stack targets every stage of tissue repair — from inflammation to collagen rebuilding. Here’s the full protocol.

All four peptides in one vial — the ultimate healing and recovery stack.

If you’re researching the most comprehensive peptide stack for tissue repair and recovery, you’ve likely come across four names together: BPC-157, TB-500, KPV, and GHK-Cu. This four-peptide combination — sometimes called the “Klow Blend” in research circles — targets virtually every phase of the healing cascade, from the initial inflammatory response right through to structural collagen remodeling.

Each peptide in this stack has a distinct mechanism of action and a specific role. That’s precisely why combining them has become so popular in the peptide research community: they don’t just overlap, they build on each other. This guide breaks down exactly what each peptide does, how they work together, and what research-based dosing protocols look like for this combination.

BPC-157: Local tissue repair + angiogenesis signaling
TB-500: Systemic cell migration + broad regeneration
KPV: Anti-inflammatory control (NF-κB inhibition)
GHK-Cu: Collagen synthesis + structural tissue remodeling

BPC-157 and TB-500 are the most discussed regenerative peptides in longevity circles. Here is what the animal research shows, how practitioners use them, and what you need to know about safety and sourcing.

BPC-157 / TB-500 (Moderate evidence) — two of the most discussed compounds in the intersection of regenerative medicine and longevity. Their appeal is straightforward: faster recovery from injuries means more consistent exercise, and consistent exercise is the single most impactful longevity intervention available. An athlete sidelined for months with a torn tendon or a weekend warrior nursing chronic tendinopathy cannot train, and the compounding effect of missed training weeks is significant over years and decades.

The challenge with discussing these peptides honestly is that the enthusiasm in the longevity community has dramatically outpaced the evidence base. BPC-157 has extensive and genuinely impressive animal research. TB-500 (synthetic thymosin beta-4) has solid wound healing data. But neither has a single published, peer-reviewed, randomized controlled trial in humans for injury recovery. This does not mean they do not work. It means we do not have the standard of evidence that normally precedes widespread adoption of a therapeutic compound.

BPC-157 (Body Protection Compound-157) is a synthetic peptide consisting of 15 amino acids derived from a protective protein found in human gastric juice. It was first characterized by Dr. Predrag Sikiric and colleagues at the University of Zagreb, who have published the majority of the research on this compound. Their work, spanning over two decades, has demonstrated healing effects across a remarkable range of tissue types in animal models.

A comprehensive review by Sikiric et al. published in Current Neuropharmacology documented BPC-157’s effects across multiple injury types:

The mechanism appears to involve modulation of the nitric oxide system, promotion of angiogenesis (new blood vessel formation), growth hormone receptor upregulation, and activation of the FAK-paxillin signaling pathway that governs cell migration and tissue repair. For the broader context of how peptides fit into longevity strategies, see our BPC-157 / TB-500 intervention page (Moderate evidence).

The critical caveat: All of this data comes from animal models. The dose translation from rats to humans is not straightforward, the injury models are artificially created, and the endpoints measured in animals do not always predict human outcomes. Dr. Sikiric’s group has conducted the vast majority of BPC-157 research, which means the findings have not been widely replicated by independent laboratories.

The combination of BPC-157 and TB-500 (Thymosin Beta-4) is the most widely used peptide stack for healing. These compounds target complementary repair pathways. For the published research, see our BPC-157 + TB-500 Research article. For general stacking principles, see our Peptide Stacking Guide.

BPC-157 and TB-500 cover different phases of tissue repair:[1]

Unit warning: BPC-157 is dosed in micrograms (mcg). TB-500 in milligrams (mg). Do not confuse the units.

See the BPC-157 Dosage Guide for detailed rationale. Use the Reconstitution Calculator for volumes.

BPC-157: Inject subcutaneously near the injury site for local concentration advantages.[2] If impractical, systemic SubQ in the abdomen works.

TB-500: Works systemically — inject anywhere (abdomen, thigh, deltoid).

They can be injected at the same time but as separate injections. For technique, see the Injection Guide.

All products third-party tested for 99%+ purity Browse Products

Detailed dosage guide for the BPC-157 and TB-500 recovery stack. Covers dose ranges, body weight adjustments, injury-specific dosing, reconstitution math, and how to adjust based on healing progress.

This article is part of our Peptide Therapy collection. See also: GLP-1 Guides | Provider Comparisons

Detailed dosage guide for the BPC-157 and TB-500 recovery stack. Covers dose ranges, body weight adjustments, injury-specific dosing, reconstitution math, and how to adjust based on healing progress.

BPC-157 is typically dosed at 250 to 500 mcg per injection once or twice daily, while TB-500 is dosed at 2 to 2.5 mg per injection once or twice weekly, with both administered subcutaneously. The exact dose depends on injury severity, body weight, treatment phase, and individual response.

Most protocols result in a total daily BPC-157 dose of 250 to 1000 mcg (0.25 to 1 mg). The twice-daily approach at 250 mcg per injection (500 mcg total daily) is the most commonly cited protocol across clinical practices.

During the loading phase, total weekly TB-500 intake is typically 4 to 5 mg. This drops to 2 to 2.5 mg during consolidation and 2 mg every two weeks during maintenance.